Kombiglyze Xr is owned by Astrazeneca Ab.
Kombiglyze Xr contains Metformin Hydrochloride; Saxagliptin Hydrochloride.
Kombiglyze Xr has a total of 3 drug patents out of which 0 drug patents have expired.
Kombiglyze Xr was authorised for market use on 05 November, 2010.
Kombiglyze Xr is available in tablet, extended release;oral dosage forms.
Kombiglyze Xr can be used as method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
The generics of Kombiglyze Xr are possible to be released after 13 July, 2025.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(4 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient
Market Authorisation Date: 05 November, 2010
Treatment: Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellit...
Dosage: TABLET, EXTENDED RELEASE;ORAL
7
United States
3
Slovenia
3
Spain
3
European Union
2
Israel
2
Denmark
2
Hong Kong
2
Hungary
2
Argentina
2
Croatia
2
Portugal
2
Cyprus
2
Korea, Republic of
2
Poland
2
Taiwan, Province of China
2
RS
2
China
2
ME
1
South Africa
1
Mexico
1
Australia
1
Russia
1
Lithuania
1
Norway
1
Brazil
1
Malaysia
1
Peru
1
Georgia
1
Ukraine
1
Japan
1
Canada
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic